Cobra venom factor: A lead venom component for the development of a biologic for the treatment of complement-mediated diseases

Toxicon ◽  
2019 ◽  
Vol 159 ◽  
pp. S6
Author(s):  
Carl-Wilhelm Vogel ◽  
David C. Fitzinger ◽  
Brian E. Hew
2015 ◽  
Vol 113 (03) ◽  
pp. 548-552 ◽  
Author(s):  
David Fritzinger ◽  
Brian Gorsuch ◽  
Gregory Stahl ◽  
Carl-Wilhelm Vogel

SummaryThe complement system is an intrinsic part of the immune system and has important functions in both innate and adaptive immunity. On the other hand, inadvertent or misdirected complement activation is also involved in the pathogenesis of many diseases, contributing solely or significantly to tissue injury and disease development. Multiple approaches to develop pharmacological agents to inhibit complement are currently being pursued. We have developed a conceptually different approach of not inhibiting but depleting complement, based on the complement-depleting activities of cobra venom factor (CVF), a non-toxic cobra venom component with structural and functional homology to complement component C3. We developed a humanised version of CVF by creating human complement component C3 derivatives with complement-depleting activities of CVF (humanised CVF) as a promising therapeutic agent for diseases with complement pathogenesis. Here we review the beneficial therapeutic effect of humanised CVF in several murine models of vascular diseases such as reperfusion injury.


1986 ◽  
Vol 261 (24) ◽  
pp. 11038-11044 ◽  
Author(s):  
P Hensley ◽  
M C O'Keefe ◽  
C J Spangler ◽  
J C Osborne ◽  
C W Vogel

Immunology ◽  
1999 ◽  
Vol 97 (1) ◽  
pp. 173-180 ◽  
Author(s):  
OBERHOLZER ◽  
YU ◽  
TRIPONEZ ◽  
CRETIN ◽  
ANDEREGGEN ◽  
...  

2011 ◽  
Vol 30 (3) ◽  
pp. 606-616 ◽  
Author(s):  
Nick S Laursen ◽  
Kasper R Andersen ◽  
Ingke Braren ◽  
Edzard Spillner ◽  
Lars Sottrup-Jensen ◽  
...  

2012 ◽  
Vol 27 (5) ◽  
pp. 301-305 ◽  
Author(s):  
Baohua Zhu ◽  
Chuanming Tong ◽  
Weitao Guo ◽  
Rong Pu ◽  
Guoping Zhang ◽  
...  

PURPOSE: To investigate synergistic suppression of donor liver pre-perfusion with recipient serum (RS) and cobra venom factor (CVF) treatment on hyperacute rejection (HAR) following liver xenotransplantation. METHODS: Guinea-pigs (GP, n=24) and Sprague-Dawley rats (SD, n=24) were recruited. Before transplantation, serum was collected from SD rats and used for preparation of inactivated complements. GP and SD rats were randomly assigned into four groups (n=6), respectively: RS group, CVF group, RS+CVF group and control group. Orthotopic liver xenotransplantation was performed with modified two-cuff technique. The survival time and liver function of recipients, morphological and pathological changes in rat livers were investigated. RESULTS: There was no piebald like change in the recipient livers in all experiment groups. The survival time of recipients in all experiment groups was longer than that in control group (p<0.05). Moreover, the survival time in the RS+CVF group was markedly longer than that in the RS group (p<0.01) and CVF group (p<0.05). The serum ALT level in all experiment groups were lower than that in the control group (p<0.05). Furthermore, the ALT level in the RS+CVF group was significantly lower than that in the CVF group (p<0.05) and RS group (p<0.01). The histological damages were significantly improved when compared with the control group, and the histological damages in the RS+CVF group were milder than those in the remaining groups (p<0.05) CONCLUSION: Pre-perfusion of donor liver with recipient serum and cobra venom factor treatment can exert synergistic suppressive effects on the hyperacute rejection following liver xenotransplantation.


Sign in / Sign up

Export Citation Format

Share Document